Skip to main content
. 2018 Mar 2;596(8):1397–1417. doi: 10.1113/JP275453

Figure 2. FOXC2 regulates LPS‐mediated DLL4 expression in HPMECs.

Figure 2

A, FOXC2 mRNA expression in HPMECs was quantified by qRT‐PCR after 3, 12 and 24 h LPS treatment, P < 0.01 (Control vs. LPS at 3 h*, 12 h** and 24 h***), n = 4. B, FOXC2 protein in HPMECs was probed by immunoblotting 24 h after treatment with LPS, and with or without TLR4‐I, n ≥ 3. C, DLL4 and FOXC2 protein were quantified by immunoblotting after 24 h LPS treatment in control siRNA or FOXC2 siRNA transfected HPMECs, with densitometry shown graphically (D), P < 0.05 (*Control vs. LPS; **LPS vs. si‐FOXC2 LPS; ***Control vs. siFOXC2 Control), n ≥ 3. E and F, FOXC2 protein was immunoprecipitated from lysates at 30 and 60 min after LPS, and serine, threonine and tyrosine phosphorylation was assessed by immunoblotting (E), and quantified by densitometry (F), P < 0.01 (Control vs. LPS at 30 min* and 60 min**), n = 3. G, HPMEC nuclear lysates obtained 30 min after LPS were used to quantify FOXC2 binding to the DLL4 promotor by the chromatin immunoprecipitation assay (ChIP), n ≥ 3. [Color figure can be viewed at http://wileyonlinelibrary.com]